Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis
Open accessThe DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index; 24 of the 199 sources its claims cite were checked for support.
Abstract
Chronic glucocorticoid (GC) treatment represents a widely-prescribed therapy for several diseases in consideration of both anti-inflammatory and immunosuppressive activity but, if used at high doses for prolonged periods, it can determine the systemic effects characteristic of Cushing’s syndrome. In addition to signs and symptoms of hypercortisolism, patients on chronic GC therapy are at risk to develop tertiary adrenal insufficiency after the reduction or the withdrawal of corticosteroids or during acute stress. This effect is mediated by the negative feedback loop on the hypothalamus-pituitary-adrenal (HPA) axis, which mainly involves corticotropin-release hormone (CRH), which represents the most important driver of adrenocorticotropic hormone (ACTH) release. In fact, after withdrawal of chronic GC treatment, reactivation of CRH secretion is a necessary prerequisite for the recovery of the HPA axis. In addition to the well-known factors which regulate the degree of inhibition of the HPA during synthetic GC therapy (type of compound, method of administration, cumulative dose, duration of the treatment, concomitant drugs which can increase the bioavailability of GCs), there is a considerable variation in individual physiology, probably related to different genetic profiles which regulate GC receptor activity. This may represent an interesting basis for possible future research fields.
Overview
CoChat Summary
TL;DR
Chronic synthetic glucocorticoid therapy can suppress the hypothalamus-pituitary-adrenal (HPA) axis and cause tertiary adrenal insufficiency, especially after dose reduction or withdrawal. Risk is shaped by compound, route, dose, duration, drug interactions, and individual genetic variation, while incidence estimates remain uncertain because diagnostic criteria vary.
Key findings
- Chronic glucocorticoids inhibit CRH and ACTH; after withdrawal, reactivation of CRH secretion is a necessary prerequisite for HPA axis recovery. A cited systematic review found hypoadrenalism persisted in 15% of patients retested three years after glucocorticoid withdrawal.
- Exposure is common: in 2008 almost 1% of the UK adult population were exposed to oral glucocorticoids, including 0.79% on long-term courses longer than three months. About 6% of hospitalized patients may have glucocorticoid-induced adrenal insufficiency, and prevalence estimates from large observational studies range from 14–63%.
- Adrenal crisis incidence was reported as 15.1/100 patient-years in tertiary adrenal insufficiency, compared with 5.2/100 patient-years in primary and 3.6/100 patient-years in secondary adrenal insufficiency. Infections were the most important precipitant, and about 30% of tertiary adrenal insufficiency crises occurred after glucocorticoid dose reduction.
- Risk predictors include prednisone >20 mg/day for >3 weeks making HPA suppression “likely,” evening/bedtime prednisone ≥5 mg for more than a few weeks also increasing risk, and 10–20 mg/day for >3 weeks being intermediate risk. Hydrocortisone and cortisone acetate are least suppressive; dexamethasone is the most potent ACTH suppressor.
Methods
- Narrative review evaluating the physiopathology and clinical effects of synthetic glucocorticoids on HPA function.
- Synthesizes literature on normal HPA physiology, synthetic glucocorticoid pharmacology, receptor biology, clinical adrenal insufficiency, and genetic variability, including cited systematic reviews, observational studies, animal models, and in vitro assays.
- No primary data collection or systematic search strategy is reported.
Limitations
- The paper states that a clear incidence of glucocorticoid-induced adrenal insufficiency cannot be assessed because of substantial differences in diagnostic criteria and variability in tests, including standard- and low-dose ACTH tests, insulin tolerance tests, and CRH stimulation, with different cut-offs and sensitivity/specificity.
- The paper notes that in vitro receptor transactivation systems differ from in vivo conditions, including steroid-metabolizing enzymes and heat shock protein concentrations, and that the literature on rapid glucocorticoid feedback is confusing and limited by not considering endogenous cortisol pulses.
- Evident from the text: as a narrative review, it does not describe a systematic search or formal quality appraisal, and many clinical estimates rely on heterogeneous cited studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Daily cortisol rhythm in healthy volunteers [23].](https://figures.cochat.ai/paper-figures/92ea4fe5961f4d21bab3c5ba7f3fae55/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-1.jpg)
![Figure 2 Corticotropin-release hormone (CRH) knock-out (KO) mouse model in regulation of hypothalamus-pituitary-adrenal (HPA) axis [59]. In CRH KO models proopiomelanocortin (POMC) mRNA, but not plasmatic adrenocorticotropic hormone (ACTH), rises after adrenalectomy. Glucocorticoids, but not mineralocorticoids (blue dotted arrow) reduce POMC increase induced by adrenalectomy. CRH administration restores a significant ACTH secretion.](https://figures.cochat.ai/paper-figures/3b5ea56302d54169a79ca7a76715b45c/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-2.jpg)
![Figure 3 Tissue side effects of synthetic glucocorticoids [1].](https://figures.cochat.ai/paper-figures/eacadeabe8df4e1faa6debafaceafd95/treatment-with-synthetic-glucocorticoids-and-the-hypothalamus-pituitary-adrenal-figure-3.jpg)
Verification
Claims the paper makes
24 Valid · 2 Not valid · 161 Not checked · 24 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“their therapeutic actions are counterbalanced by adverse side effects associated with high doses and long-term use, such as osteoporosis, skin atrophy, diabetes, hypertension, abdominal obesity, acne, infection, and growth retardation [8], as well as ocular hypertension [9].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 1. Introduction
What the sources say
- Not checked yetcites [8] Schacke H. Docke W.D. Asadullah K. Mechanisms involved in the side effects of glucocorticoids Pharmacol. Ther. 2002 96 23 43 10.1016/S0163-7258(02)00297-8 12441176 source
- Supportedcites [9] Dibas A. Yorio T. Glucocorticoid therapy and ocular hypertension Eur. J. Pharmacol. 2016 787 57 71 10.1016/j.ejphar.2016.06.018 27388141 PMC5014726 source
The citation [9] is attached specifically to the 'ocular hypertension' element of the citing sentence (the systemic side-effect list is credited to [8]). Our copy supports that attribution directly: the Introduction (Section 1) states that chronic GC use is associated with deleterious side effects including glaucoma/cataracts, Section 6 ('Mechanism of steroid-induced secondary ocular hypertension') documents GC-induced IOP elevation occurring within hours, weeks (topical) or years (systemic), and the Conclusion (Section 10) affirms that 'the side effect of increasing intraocular pressure remains a great risk to develop glaucoma'. No contrary statement was found; the other listed effects (abdominal obesity, acne, infection, systemic hypertension) are not attributed to this source, so they do not weaken the verdict. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Interestingly, novel treatments aimed at improving the benefit/risk ratio of GCs therapy (selective GC receptor agonists, SEGRAs), which are currently being trialed, are unlikely to alter the risk of adrenal insufficiency.”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.1. Synthetic Glucocorticoids
What the sources say
- Partly supportedcites [36] Schacke H. Schottelius A. Docke W.D. Strehlke P. Jaroch S. Schmees N. Rehwinkel H. Hennekes H. Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects Proc. Natl. Acad. Sci. USA 2004 101 227 232 10.1073/pnas.0300372101 14694204 PMC314167 sourceExperimental — accuracy not yet measured
The Results report that the SEGRA ZK 216348 suppressed ACTH in rats about as effectively as prednisolone. The Discussion says the authors do not expect this compound class to have an advantage over standard glucocorticoids in suppressing the hypothalamo-pituitary-adrenal axis. The paper does not measure adrenal insufficiency risk in patients and says clinical studies are needed to determine whether its findings translate to humans. (LLM, conf=0.84)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“This is probably because adrenal insufficiency can develop with the same mechanism, mediating the “therapeutic” anti-inflammatory effects of these compounds [36].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.1. Synthetic Glucocorticoids
What the sources say
- Supportedcites [36] Schacke H. Schottelius A. Docke W.D. Strehlke P. Jaroch S. Schmees N. Rehwinkel H. Hennekes H. Asadullah K. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects Proc. Natl. Acad. Sci. USA 2004 101 227 232 10.1073/pnas.0300372101 14694204 PMC314167 source
The Abstract/Introduction of our copy states that 'the antiinflammatory effects are mediated to a major extent via transrepression' while 'a key mechanism for suppression of the hypothalamo-pituitary-adrenal axis, the decreased release of adrenocorticotropic hormone (ACTH) by corticotrophin-releasing hormone, is mediated by the GR via a transrepression mechanism.' The Discussion (and Abstract) confirm this consequence: the SEGRA ZK 216348 retained HPA-axis/ACTH suppression comparable to prednisolone precisely because that side effect shares the transrepression mechanism of the therapeutic effect. The paper phrases the outcome as HPA-axis/ACTH suppression (with adrenal weight reduction as a related measure) rather than 'adrenal insufficiency,' but the mechanism-identity the claim attributes is stated. (LLM, conf=0.85)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Mice with a specific GR-deletion in the forebrain show HPA axis hyperactivity; basal cortisol is increased, as well as post-stress cortisol and ACTH levels [57].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.2. Negative Feedback Loop and Glucocorticoid Receptors
What the sources say
- Partly supportedcites [57] Arnett M.G. Muglia L.M. Laryea G. Muglia L.J. Genetic approaches to hypothalamic-pituitary-adrenal axis regulation Neuropsychopharmacology 2016 41 245 260 10.1038/npp.2015.215 26189452 PMC4677126 sourceExperimental — accuracy not yet measured
The “Forebrain GR deletion” section reports HPA-axis hyperactivity and increased basal and post-stress cort and post-stress ACTH in male forebrain-GR-deletion mice. It also says female mice showed no increase in basal or stress-induced cort, so the claim is too broad without the male qualifier. The paper calls the measured hormone “cort,” not cortisol. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Moved to clinical practice, this model helps to understand that, in adrenal insufficiency, loss of GC feedback, by itself, can increase POMC gene expression in the pituitary (suggesting that CRH is not absolutely required for changes in POMC expression in response to absolute GC deficiency), but CRH action is essential to guarantee the increase of ACTH secretion.”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.2. Negative Feedback Loop and Glucocorticoid Receptors
What the sources say
- Supportedcites [59] Muglia L.J. Jacobson L. Luedke C. Vogt S.K. Schaefer M.L. Dikkes P. Fukuda S. Sakai Y. Suda T. Majzoub J.A. Corticotropin-releasing hormone links pituitary adrenocorticotropin gene expression and release during adrenal insufficiency J. Clin. Investig. 2000 105 1269 1277 10.1172/JCI5250 10792002 PMC315436 source
The Discussion states that POMC mRNA increased after adrenalectomy in CRH-deficient mice and explicitly concludes that CRH is not absolutely required for changes in POMC expression in response to absolute glucocorticoid deficiency. The Introduction likewise says loss of glucocorticoid feedback can increase pituitary POMC gene expression without CRH. (LLM, conf=0.95)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
146 more claims · 15 with their cited sources checked
Create a free account to see all 211 claims and to verify the 175 references still open.
- Probably not a substantial claim. 13
- It may state two separate claims as one. 52
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is potentially linked to its pharmacokinetics (long half-life of 14.4 hours) and pharmacodynamics (binding affinity to the glucocorticoid receptors 18 times that of dexamethasone) (112).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [112]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > 3. Effects of Glucocorticoids Therapy on the Hypothalamus–Pituitary–Adrenal Axis > 3.3. Clinical Consequence: Tertiary Hypoadrenalism and Adrenal Crisis
“the risk of suppressed adrenal function after a seven-day prednisone treatment is increased in subjects who have a low cortisol level after a dexamethasone suppression test [84].”
§ Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis > References
“84. Neidert S. Schuetz P. Mueller B. Christ-Crain M. Dexamethasone suppression test predicts later development of an impaired adrenal function after a 14-day course of prednisone in healthy volunteers”
Citations
Cites
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149 · cited 2×
“Named for their effect on carbohydrate metabolism, glucocorticoids (GCs) regulate different cellular functions as homeostasis, metabolism, development, cognition, and inflammation [1].”
BackgroundThe Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458 · cited 3×
“StAR protein, in turn, mediates the translocation of cholesterol to the inner mitochondrial membrane, where the first steroidogenic enzyme is located [18].”
BackgroundMechanisms involved in the side effects of glucocorticoids
SCHACKE, H. (2002) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00297-8 · Cited by 1,847 · cited 1×
“Unfortunately, their therapeutic actions are counterbalanced by adverse side effects associated with high doses and long-term use, such as osteoporosis, skin atrophy, diabetes, hypertension, abdominal obesity, acne, infection, and growth retardation [8], as well as ocular hypertension [9].”
BackgroundImmune regulation by glucocorticoids
Cain, D. W., & Cidlowski, J. A. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.1 · Cited by 1,846
Regulation of the Hypothalamic‐Pituitary‐Adrenocortical Stress Response
Herman, J. P., McKlveen, J. M., Ghosal, S., Kopp, B., Wulsin, A., Makinson, R., Scheimann, J., & Myers, B. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c150015 · Cited by 1,819
Corticosteroid inhibition of acth secretion
KELLER-WOOD, M. E., & DALLMAN, M. F. (1984) · Endocrine Reviews · doi:10.1210/edrv-5-1-1 · Cited by 1,219
Effects of gender and age on the levels and circadian rhythmicity of plasma cortisol
Van Cauter, E. (1996) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.7.2468 · Cited by 951 · cited 1×
“No difference in physiological cortisol secretion is related to weight or gender [21].”
Background11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887 · cited 1×
“MR expression shows a restricted tissue distribution, with high expression in classical aldosterone target organs, such as kidney, colon, salivary glands, and specific brain regions, and more modest expression in heart, vascular tissues, adipocytes, and specific immune cell populations [52].”
BackgroundKarst, H., Berger, S., Turiault, M., Tronche, F., Schütz, G., & Joëls, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507572102 · Cited by 774 · cited 2×
“However, the literature on the mechanism of rapid GC inhibition of HPA activity is confusing: in rats, there is in vivo evidence that this involves a MR-mediated process [63], but ex vivo studies suggest no MR involvement [66].”
BackgroundRamamoorthy, S., & Cidlowski, J. A. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2015.08.002 · Cited by 692 · cited 1×
“The discovery that there are multiple GR isoforms generated by alternative splicing [90] leads to understanding the molecular basis for this different sensitivity to GC [91].”
Background
Cited by
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Chronopharmacology of glucocorticoids
Scherholz, M. L., Schlesinger, N., & Androulakis, I. P. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.004 · Cited by 144
“A brief summary of pharmacodynamics for select glucocorticoids are provided in Table 3 (adapted from [75]).”
BackgroundBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Role of the Hypothalamic–Pituitary–Adrenal Axis in Health and Disease
DeMorrow, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19040986 · Cited by 119
“[14] Treatment with Synthetic Glucocorticoids and the Hypothalamus–Pituitary–Adrenal Axis Synthetic glucocorticoid, tertiary hypoadrenalism, iatrogenic Cushing’s syndrome Review”
MethodBeuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 156
Metadata
- Authors
- Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Corresponding author
- Corsello, Salvatore Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-10-20
- Volume
- 18
- Issue
- 10
- Pages
- 2201
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5666882
- OpenAlex
- W2765223108
- Semantic Scholar
- ad19ea2188368acba719dc110c72abdf5db33d87
- Cited by
- 181
- References
- 93
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 23 · 2023: 23 · 2022: 25 · 2021: 34 · 2020: 16 · 2019: 23 · 2018: 10 · 2017: 1
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- synthetic glucocorticoids, hypothalamic-pituitary-adrenal axis, Cushing's syndrome, tertiary adrenal insufficiency, corticotropin-releasing factor, ACTH, glucocorticoid withdrawal
- MeSH terms
- Adrenocorticotropic Hormone, Animals, Corticotropin-Releasing Hormone, Cushing Syndrome, Glucocorticoids, Humans, Hypothalamo-Hypophyseal System, Pituitary-Adrenal System, Feedback, Physiological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis. https://app.cochat.ai/papers/10.3390/ijms18102201
- The paper
- Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017). Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18102201
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.